Legislative, Regulatory & Legal

NACDS, and NCPA reacted with disapproval after a final drug pricing rule excluded reforms to pharmacy DIR fees.

CMS' new guidance clarifies how current regulations require “spread pricing” to be accounted for in the calculation of Medical Loss Ratios.

Walmart posted net income of $3.84 billion, or $1.33 a share, in the quarter ended April 26, up from $2.13 billion, or .72 cents a share from a year ago.

The Association for Accessible Medicines has sent two letters to Capital Hill in advance of House consideration of H.R. 987.

Teva is expected to launch its generic of Gilead's Truvada one year earlier than expected.

The increase is expected to leave many retailers in a crunch as they plan for the 2019 holiday season, scrambling to make purchase orders and set prices, CNBC reported.

The Association for Accessible Medicines said the Food and Drug Administration's guidance on naming biological products delays the development of biosimilars.

NACDS' Steve Anderson continues to urge for DIR fee reform in anticipation of a Medicare rule that would provide relief from DIR fees.